News Updates

More Articles Back to Article

Pfizer backs Ribon Therapeutics with $25M investment

Pfizer has invested $25 million in Ribon Therapeutics, which the latter will use to develop therapeutics that target stress support pathways for oncology and immunology, particularly its oral small molecule programs. "Pfizer's capital support and expertise will be instrumental as we work to advance our lead programs--RBN-2397 in cancer and RBN-3143 in immunology--to key clinical milestones and enable further drug discovery and development from our proprietary Beacon+ platform," said Prakash Raman, Ribon Therapeutics president and CEO. Becker's Hospital Review (1/30)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!